Join Growin Stock Community!
Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-flow-chart

PFE Cash Flow

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q1'26, Pfizer's (PFE) Operating Cash Flow reached $2.615B USD, reflecting a positive but moderated performance compared to the prior quarter's $5.348B USD in Q4'25, while Free Cash Flow stood at $2.179B USD, indicating sustained cash generation after capital expenditures. This latest data point covers the period ending March 29, 2026, and shows both metrics remaining in positive territory despite seasonal fluctuations. Over the timeframe from Q2'23 to Q1'26, Operating Cash Flow exhibited high volatility, starting with a -$1.208B USD deficit in Q2'23, surging to peaks of $6.721B USD in Q3'24 and $6.721B USD in Q4'24, but dipping into negatives like -$1.781B USD in Q2'24 and -$0.582B USD in Q2'25, before stabilizing with consistent positives in recent quarters averaging around $4B USD. Free Cash Flow followed a similar erratic pattern, with early losses of -$2.122B USD in Q2'23 offset by strong gains up to $6.063B USD in Q3'24, and notable declines in Q2'24 (-$2.418B USD) and Q2'25 (-$1.2B USD), yet trending toward recovery with values exceeding $2B USD in the last three quarters, highlighting operational resilience amid investment cycles in this bar chart visualization.